Stock RYTM RHYTHM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Real-time Estimate Cboe BZX
Other stock markets
 01:56:31 2024-06-10 pm EDT 		5-day change 1st Jan Change
39.78 USD -0.46% Intraday chart for Rhythm Pharmaceuticals, Inc. +5.32% -13.28%
03:20pm Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
May. 22 Rhythm Pharmaceuticals' Imcivree Gains UK Recommendation for Treating Bardet-Biedl Syndrome MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
GL
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
AQ
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for IMCIVREE for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
AQ
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals : RYTM 1Q2024 vFinal
PU
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
GL
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
GL
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
AQ
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
GL
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
GL
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
GL
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
AQ
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
AQ
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
GL
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
GL
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RYTM Stock
  4. News Rhythm Pharmaceuticals, Inc.
  5. Press Releases